CRISPR/Cas9 technology generated an AGG to CAA change at residues 310-312 resulting in an arginine to glutamine substitution at amino acid 104 (R104Q). This is a mutation seen in progressive myoclonus epilepsy. (J:321396)
Legend:
cx: complex: > 1 genome feature ot: other: hemizygous, indeterminate,... (F): Female
(M): Male
N: normal phenotype
(#): related diseases count